colorful burb

Analysis

Life sciences and health care M&A Update: Q3 2024

Digital technologies like telemedicine, remote monitoring, wearables, and virtual wards are transforming healthcare delivery, empowering patients to take control of their health and driving better outcomes.

Life sciences and health care trends

  • Health care services
    Healthcare stakeholders are leveraging real-time, harmonized data to innovate healthcare and disease-prevention strategies, overcoming data silos to enhance patient outcomes and population health.1
  • Health care technology
    Nanomedicine is a growing trend in healthcare technology, which achieves precision in diagnostics, treatment, and disease prevention.2
  • Life sciences and pharma services
    Life sciences and pharma services are heavily investing in AI tools, data pipelines, and analytics to speed up drug discovery and development.3
  • Medical devices and supplies
    The global emphasis on fitness and the focus of healthcare agencies on monitoring and diagnosis is driving demand for fitness trackers.4
  • Payors and payor services
    Increasing health insurance enrollments due to the Patient Protection and Affordable Care Act (PPACA), rising federal healthcare mandates, the prevalence of chronic diseases, and growing healthcare fraud is driving market growth.5

This newsletter is a periodic compilation of certain capital markets information. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy, or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties, and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have “long” and “short” positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Did you find this useful?